Winter 2021 | CURE

Examining Racial and Ethnic Disparities in Cancer Care

February 19, 2021

Editor's Page

The past year has spotlighted racial inequities not only in the U.S., but worldwide. It has also opened our eyes as to how a major health disruption — in this case, a pandemic — can aggravate the unacceptable status quo.

Age May Not Impact Outcomes from Metastatic Renal Cell Carcinoma Treatment Despite Increased Toxicity in Older Patients

January 11, 2021

Patients older than 75 years experienced more toxicity with mTOR inhibitors, tyrosine kinase inhibitors and checkpoint immunotherapy compared with those younger than 75 years, but researchers found that age did not impact outcomes like progression-free survival and overall survival.

Venclexta-Rituxan Combo Continues to Show Survival Benefit Through 5 Years in Relapsed/Refractory CLL

December 05, 2020

Compared with patients assigned bendamustine with Rituxan, those assigned Venclexta with Rituxan maintained an overall survival benefit, with a five-year OS estimate of 82.1% for the Venclexta with Rituxan group vs. 62.2% for the bendamustine with Rituxan group.

Immunotherapy 101: What Patients Can Expect from CAR-T Cell Therapy

December 03, 2020

Chimeric antigen receptor (CAR)-T cell therapy is becoming more widely available, with two drugs approved to treat specific blood cancers and more being investigated in clinical trials across cancer types. Here’s what patients need to know if they’re considering treatment with one of these novel immunotherapies.

Adding Tukysa to Regimen for Metastatic HER2-Positive Breast Cancer Does Not Decrease Quality of Life

October 08, 2020

Adding the targeted drug Tukysa (tucatinib) to Herceptin (trastuzumab) and the chemotherapy Xeloda (capecitabine) lengthens life and time until disease progression in patients, without decreasing their health-related quality of life, researchers found in a follow-up to the HER2CLIMB study.